StreetInsider.com News Articles

Form 4 Travere Therapeutics, For: Aug 17 Filed by: LYONS GARY A

Wed, 19 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260819/26950030.html

Form 4 Travere Therapeutics, For: Aug 17 Filed by: LYONS GARY A

Wed, 19 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260819/26950030.html

Form 144 Travere Therapeutics, Filed by: LYONS GARY A

Tue, 18 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260818/26944619.html

Form 144 Travere Therapeutics, Filed by: LYONS GARY A

Tue, 18 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260818/26944619.html

Form 144 Travere Therapeutics, Filed by: LYONS GARY A

Mon, 17 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26938402.html

Form 144 Travere Therapeutics, Filed by: LYONS GARY A

Mon, 17 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26938402.html

Travere Therapeutics (TVTX) PT Raised to $68 at Piper Sandler

Mon, 17 Aug 2026 07:44:02 -0400

Piper Sandler analyst Allison M. Bratzel raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $68.00 (from $49.00) while maintaining a Overweight rating.

Form SCHEDULE 13G/A Travere Therapeutics, Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26926439.html

Form SCHEDULE 13G/A Travere Therapeutics, Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26926439.html

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 12 Aug 2026 17:00:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 12 Aug 2026 17:00:00 -0400

The RSUs vest

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 12 Aug 2026 17:00:00 -0400

The RSUs vest

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 12 Aug 2026 17:00:00 -0400

The RSUs vest

Form SCHEDULE 13G Travere Therapeutics, Filed by: BANK OF AMERICA CORP /DE/

Wed, 12 Aug 2026 13:29:00 -0400

si-local-file:///var/storage/secattach/20260812/26911698.html

Form SCHEDULE 13G Travere Therapeutics, Filed by: BANK OF AMERICA CORP /DE/

Wed, 12 Aug 2026 13:29:00 -0400

si-local-file:///var/storage/secattach/20260812/26911698.html

Form SCHEDULE 13G Travere Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26889255.html

Form SCHEDULE 13G Travere Therapeutics, Filed by: STATE STREET CORP

Fri, 07 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260807/26889255.html

Form SCHEDULE 13G/A Travere Therapeutics, Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881430.html

Form SCHEDULE 13G/A Travere Therapeutics, Filed by: FMR LLC

Thu, 06 Aug 2026 10:44:00 -0400

si-local-file:///var/storage/secattach/20260806/26881430.html

Travere Therapeutics (TVTX) PT Raised to $70 at Canaccord

Thu, 06 Aug 2026 06:42:21 -0400

Canaccord analyst Ed Nash raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $70.00 (from $62.00) while maintaining a Buy rating.

Travere Therapeutics (TVTX) PT Raised to $80 at Wells Fargo

Thu, 06 Aug 2026 06:38:23 -0400

Wells Fargo analyst Mohit Bansal raised the price target on Travere Therapeutics (NASDAQ: TVTX) to $80.00 (from $65.00) while maintaining a Overweight rating.

Travere Therapeutics to Participate at Upcoming Investor Conferences

Wed, 05 Aug 2026 16:30:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Canaccord Genuity's 46th Annual Growth Conference
Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET

Wells Fargo 21st Annual Healthcare Conference
Tuesday, September 8, 2026

Citi 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026

2026 Cantor Global Healthcare Conference
Presenting on Thursday, September 10, 2026, at 9:10 a.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30

Travere Therapeutics to Participate at Upcoming Investor Conferences

Wed, 05 Aug 2026 16:30:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Canaccord Genuity's 46th Annual Growth Conference
Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET

Wells Fargo 21st Annual Healthcare Conference
Tuesday, September 8, 2026

Citi 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026

2026 Cantor Global Healthcare Conference
Presenting on Thursday, September 10, 2026, at 9:10 a.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30

Travere Therapeutics to Participate at Upcoming Investor Conferences

Wed, 05 Aug 2026 16:30:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Canaccord Genuity's 46th Annual Growth Conference
Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET

Wells Fargo 21st Annual Healthcare Conference
Tuesday, September 8, 2026

Citi 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026

2026 Cantor Global Healthcare Conference
Presenting on Thursday, September 10, 2026, at 9:10 a.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30

Travere Therapeutics to Participate at Upcoming Investor Conferences

Wed, 05 Aug 2026 16:30:00 -0400

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Canaccord Genuity's 46th Annual Growth Conference
Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET

Wells Fargo 21st Annual Healthcare Conference
Tuesday, September 8, 2026

Citi 2026 Biopharma Back to School Conference
Wednesday, September 9, 2026

2026 Cantor Global Healthcare Conference
Presenting on Thursday, September 10, 2026, at 9:10 a.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30